{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:57:26Z","timestamp":1793750246351,"version":"4.6.1"},"reference-count":34,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,22]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Hydroxyurea is the primary disease-modifying medication for sickle cell anemia (SCA), but its long-term effects, particularly how these effects change over time, are not well understood. This study aimed to quantify the effects of hydroxyurea on clinical and laboratory outcomes in children with SCA over a prolonged period of use. We conducted a quasi-experimental study using contemporary difference-in-differences and dynamic event study analyses on a longitudinal cohort of 2147 children with SCA (hemoglobin SS or hemoglobin SS\u03b20, HbSS\/HbS\u03b20) from 2010 to 2021. The primary outcomes included emergency department (ED) visits per year, hospital days per year, and annual average hemoglobin concentration. Hydroxyurea use was associated with fewer ED visits per year (average treatment effect on the treated [ATT], \u22120.36 visit per year; 95% confidence interval [CI], \u22120.57 to \u22120.16) and fewer hospital days per year (ATT, \u22120.84 d\/y; 95% CI, \u22121.51 to \u22120.17) with sustained effects over time. On average, the hemoglobin concentration increased with hydroxyurea use (ATT, 0.56 g\/dL; 95% CI, 0.39-0.73), but the sustained effect was observed only among the subgroup with laboratory markers of good adherence. This study demonstrates that hydroxyurea has sustained clinical benefits in reducing ED visits and hospital days across years of use in children with SCA. These findings provide perspective for clinicians and families regarding the long-term efficacy of hydroxyurea in pediatric SCA management and underscore the importance of ongoing adherence counseling to optimize clinical benefit. Furthermore, this study design provides a methodological framework for rigorously and causally evaluating other SCA-specific treatments, such as stem cell transplant and gene therapy, in real-world settings.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015564","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T13:00:50Z","timestamp":1744808450000},"page":"3585-3593","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Evaluating the long-term benefits of hydroxyurea in pediatric sickle cell anemia"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7209-2827","authenticated-orcid":false,"given":"Paul","family":"George","sequence":"first","affiliation":[{"name":"1Division of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, GA"},{"name":"2Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta, Atlanta, GA"},{"name":"3Department of Pediatrics, School of Medicine, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Kalmus","sequence":"additional","affiliation":[{"name":"2Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Lane","sequence":"additional","affiliation":[{"name":"2Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta, Atlanta, GA"},{"name":"3Department of Pediatrics, School of Medicine, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0325-7990","authenticated-orcid":false,"given":"Wilbur","family":"Lam","sequence":"additional","affiliation":[{"name":"2Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta, Atlanta, GA"},{"name":"3Department of Pediatrics, School of Medicine, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Lipscomb","sequence":"additional","affiliation":[{"name":"1Division of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Howard","sequence":"additional","affiliation":[{"name":"1Division of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"issue":"2","key":"2025072114013217900_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12288-013-0261-4","article-title":"Hydroxyurea in sickle cell disease: drug review","volume":"30","author":"Agrawal","year":"2014","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"11","key":"2025072114013217900_bib2","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1517\/14740338.2015.1088827","article-title":"Hydroxyurea therapy for sickle cell anemia","volume":"14","author":"McGann","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"20","key":"2025072114013217900_bib3","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N Engl J Med"},{"issue":"1","key":"2025072114013217900_bib4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ajh.24587","article-title":"Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: a large retrospective, population-based cohort","volume":"92","author":"Quarmyne","year":"2017","journal-title":"Am J Hematol"},{"issue":"9778","key":"2025072114013217900_bib5","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)","volume":"377","author":"Wang","year":"2011","journal-title":"The Lancet"},{"issue":"10","key":"2025072114013217900_bib6","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members","volume":"312","author":"Yawn","year":"2014","journal-title":"JAMA"},{"issue":"6","key":"2025072114013217900_bib7","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ajh.21699","article-title":"The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up","volume":"85","author":"Steinberg","year":"2010","journal-title":"Am J Hematol"},{"issue":"7","key":"2025072114013217900_bib8","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-12-4973","article-title":"Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study","volume":"106","author":"Hankins","year":"2005","journal-title":"Blood"},{"issue":"10019","key":"2025072114013217900_bib9","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(15)01041-7","article-title":"Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia\u2014TCD with transfusions changing to hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial","volume":"387","author":"Ware","year":"2016","journal-title":"The Lancet"},{"issue":"17","key":"2025072114013217900_bib10","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1182\/blood-2011-11-392340","article-title":"Stroke with transfusions changing to hydroxyurea (SWiTCH)","volume":"119","author":"Ware","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2025072114013217900_bib11","first-page":"125","article-title":"Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes","volume":"91","author":"de Montalembert","year":"2006","journal-title":"Haematologica"},{"issue":"11","key":"2025072114013217900_bib12","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/pbc.25608","article-title":"Survival among children and adults with sickle cell disease in Belgium: benefit from hydroxyurea treatment","volume":"62","author":"L\u00ea","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"15","key":"2025072114013217900_bib13","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1056\/NEJM199004123221504","article-title":"Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea","volume":"322","author":"Rodgers","year":"1990","journal-title":"N Engl J Med"},{"issue":"26","key":"2025072114013217900_bib14","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1056\/NEJMoa2000146","article-title":"Hydroxyurea dose escalation for sickle cell anemia in sub-Saharan Africa","volume":"382","author":"John","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"2025072114013217900_bib15","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood.2022017051","article-title":"Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa","volume":"141","author":"Olupot-Olupot","year":"2023","journal-title":"Blood"},{"issue":"9","key":"2025072114013217900_bib16","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/ajh.22101","article-title":"Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease","volume":"86","author":"Brandow","year":"2011","journal-title":"Am J Hematol"},{"issue":"1","key":"2025072114013217900_bib17","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12955-017-0713-x","article-title":"Adherence to hydroxyurea, health-related quality of life domains, and patients\u2019 perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults","volume":"15","author":"Badawy","year":"2017","journal-title":"Health Qual Life Outcomes"},{"issue":"9","key":"2025072114013217900_bib18","doi-asserted-by":"crossref","first-page":"e30453","DOI":"10.1002\/pbc.30453","article-title":"Are children with sickle cell disease at particular risk from the harmful effects of air pollution? Evidence from a large, urban\/peri-urban cohort","volume":"70","author":"George","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2025072114013217900_bib19","doi-asserted-by":"crossref","first-page":"e2021051892","DOI":"10.1542\/peds.2021-051892","article-title":"Bloodstream infections in children with sickle cell disease: 2010-2019","volume":"149","author":"Yee","year":"2022","journal-title":"Pediatrics"},{"issue":"2","key":"2025072114013217900_bib20","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jeconom.2020.12.001","article-title":"Difference-in-Differences with multiple time periods","volume":"225","author":"Callaway","year":"2021","journal-title":"J Econom"},{"key":"2025072114013217900_bib21","unstructured":"Wooldridge\n              JM\n            \n          . Two-way fixed effects, the two-way mundlak regression, and difference-in-differences estimators. Accessed 9 July 2023. https:\/\/papers.ssrn.com\/sol3\/papers.cfm?abstract_id=3906345."},{"key":"2025072114013217900_bib22","author":"Angrist","year":"2009","edition":"1st ed"},{"issue":"4","key":"2025072114013217900_bib23","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0022-3476(76)80390-3","article-title":"Developmental change in red blood cell volume: implication in screening infants and children for iron deficiency and thalassemia trait","volume":"89","author":"Koerper","year":"1976","journal-title":"J Pediatr"},{"issue":"2","key":"2025072114013217900_bib24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jeconom.2020.09.006","article-title":"Estimating dynamic treatment effects in event studies with heterogeneous treatment effects","volume":"225","author":"Sun","year":"2021","journal-title":"J Econom"},{"key":"2025072114013217900_bib25","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.2207.05943","article-title":"","author":"Gardner","year":"13  2022","journal-title":"Two-stage differences in differences"},{"issue":"6","key":"2025072114013217900_bib26","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood.V88.6.1960.bloodjournal8861960","article-title":"Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial","volume":"88","author":"Ferster","year":"1996","journal-title":"Blood"},{"issue":"22","key":"2025072114013217900_bib27","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1182\/blood-2012-03-419879","article-title":"Impact of hydroxyurea on clinical events in the BABY HUG trial","volume":"120","author":"Thornburg","year":"2012","journal-title":"Blood"},{"key":"2025072114013217900_bib29","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bcmd.2017.08.017","article-title":"Real-life experience with hydroxyurea in sickle cell disease: a multicenter study in a cohort of patients with heterogeneous descent","volume":"69","author":"Rigano","year":"2018","journal-title":"Blood Cell Mol Dis"},{"issue":"6","key":"2025072114013217900_bib30","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1182\/blood-2003-07-2475","article-title":"Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease","volume":"103","author":"Zimmerman","year":"2004","journal-title":"Blood"},{"issue":"28","key":"2025072114013217900_bib31","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1097\/MD.0000000000000215","article-title":"From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia","volume":"93","author":"Hankins","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"2025072114013217900_bib32","doi-asserted-by":"crossref","first-page":"e0199375","DOI":"10.1371\/journal.pone.0199375","article-title":"From trust to skepticism: an in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea","volume":"13","author":"Sinha","year":"2018","journal-title":"PLOS ONE"},{"issue":"2","key":"2025072114013217900_bib33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/pbc.24178","article-title":"Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children","volume":"59","author":"Strouse","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2025072114013217900_bib34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2307\/1924332","article-title":"Estimating the effect of training programs on earnings","volume":"60","author":"Ashenfelter","year":"1978","journal-title":"Rev Econ Stat"},{"issue":"6","key":"2025072114013217900_bib35","doi-asserted-by":"crossref","first-page":"e0304644","DOI":"10.1371\/journal.pone.0304644","article-title":"Study protocol for ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness): using small business partnerships to deliver a scalable and novel hydroxyurea adherence solution to youth with sickle cell disease","volume":"19","author":"Walden","year":"2024","journal-title":"PLoS One"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/14\/3585\/2402762\/blooda_adv-2024-015564-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/14\/3585\/2402762\/blooda_adv-2024-015564-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T18:01:43Z","timestamp":1753120903000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/14\/3585\/536727\/Evaluating-the-long-term-benefits-of-hydroxyurea"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":34,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2025,7,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015564","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,22]]},"published":{"date-parts":[[2025,7,14]]}}}